Sublingual Sufentanil May Reduce Risk for Psychiatric Sequalae and Chronic Pain Following Combat Trauma: Editorial for the Newest Battlefield Opioid, Sublingual Sufentanil
Mil Med
.
2022 Jul 1;187(7-8):217-218.
doi: 10.1093/milmed/usac053.
Authors
Sharon Y Kim
1
2
,
Chester C Buckenmaier Iii
1
3
,
Edmund Howe
1
4
5
,
Kwang Choi
2
4
5
Affiliations
1
School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
2
Program in Neuroscience, Uniformed Services University, Bethesda, MD 20814, USA.
3
Department of Anesthesiology, Uniformed Services University, Bethesda, MD 20814, USA.
4
Department of Psychiatry, Uniformed Services University, Bethesda, MD 20814, USA.
5
Center for the Study of Traumatic Stress, Uniformed Services University, Bethesda, MD 20814, USA.
PMID:
35266520
DOI:
10.1093/milmed/usac053
No abstract available
Publication types
Letter
MeSH terms
Analgesia, Patient-Controlled
Analgesics, Opioid / therapeutic use
Chronic Pain* / drug therapy
Chronic Pain* / etiology
Humans
Pain, Postoperative
Sufentanil*
Substances
Analgesics, Opioid
Sufentanil